Corrigendum to”Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer”. [Redox Biol 10 (2016) 78–89 [201222–008501] [211009–007504] (Redox Biology (2016) 10 (78–89), (S2213231716301331), (10.1016/j.redox.2016.09.006));Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer

Redox Biology

Volumn 10, Issue , 2016, Pages 78-89

  Chen, Weiqian ^a,b   Zou, Peng ^a,c   Zhao, Zhongwei ^b   Chen, Xi ^a   Fan, Xiaoxi ^b   Vinothkumar, Rajamanickam ^a   Cui, Ri ^a   Wu, Fazong ^b   Zhang, Qianqian ^b   Liang, Guang ^a,c   Ji, Jiansong ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

^c NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor; Cytotoxicity; EF24; Gastric cancer; Oxidative stress; Rapamycin

Indexed keywords

3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; 3,5-BIS(2-FLUOROBENZYLIDENE)PIPERIDIN-4-ONE; ANTINEOPLASTIC AGENT; BENZYLIDENE DERIVATIVE; PIPERIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STOMACH CANCER; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZYLIDENE COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; PIPERIDONES; REACTIVE OXYGEN SPECIES; SIROLIMUS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84989172653     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2021.102191     Document Type: Erratum

References (39)

1. [1] Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127:12 (2010), 2893–2917.
2. [2] Wagner, A.D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., Fleig, W.E., Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24:18 (2006), 2903–2909.
3. [3] Power, D.G., Kelsen, D.P., Shah, M.A., Advanced gastric cancer – slow but steady progress. Cancer Treat. Rev. 36:5 (2010), 384–392.
4. [4] Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur. J. Surg. Oncol.: J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 40:5 (2014), 584–591.
5. [5] Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24:31 (2006), 4991–4997.
6. [6] Bouche, O., Ychou, M., Burtin, P., Bedenne, L., Ducreux, M., Lebreton, G., Baulieux, J., Nordlinger, B., Martin, C., Seitz, J.F., et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 16:9 (2005), 1488–1497.
7. [7] Vezina, C., Kudelski, A., Sehgal, S.N., Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28:10 (1975), 721–726.
8. [8] Douros, J., Suffness, M., New antitumor substances of natural origin. Cancer Treat. Rev. 8:1 (1981), 63–87.
9. [9] Meric, F., Hunt, K.K.:, Translation initiation in cancer: a novel target for therapy. Mol. Cancer Ther. 1:11 (2002), 971–979.
10. [10] Shigematsu, H., Yoshida, K., Sanada, Y., Osada, S., Takahashi, T., Wada, Y., Konishi, K., Okada, M., Fukushima, M., Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int. J. Cancer 126:11 (2010), 2716–2725.
11. [11] Populo, H., Lopes, J.M., Soares, P., The mTOR signalling pathway in human cancer. Int J. Mol. Sci. 13:2 (2012), 1886–1918.
12. [12] Zou, P., Chen, M., Ji, J., Chen, W., Chen, X., Ying, S., Zhang, J., Zhang, Z., Liu, Z., Yang, S., et al. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. Oncotarget 6:34 (2015), 36505–36521.
13. [13] Zou, P., Xia, Y., Chen, W., Chen, X., Ying, S., Feng, Z., Chen, T., Ye, Q., Wang, Z., Qiu, C., et al. EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells. Oncotarget, 2016.
14. [14] Zou, P., Zhang, J., Xia, Y., Kanchana, K., Guo, G., Chen, W., Huang, Y., Wang, Z., Yang, S., Liang, G., ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer. Oncotarget 6:8 (2015), 5860–5876.
15. [15] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:2 (2011), 85–95.
16. [16] DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:7354 (2011), 106–109.
17. [17] Trachootham, D., Alexandre, J., Huang, P., Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 8:7 (2009), 579–591.
18. [18] Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., Le Bras, M., Duffort, S., Peres, L., Berthier, C., Soilihi, H., Raught, B., et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18:1 (2010), 88–98.
19. [19] Alexandre, J., Hu, Y., Lu, W., Pelicano, H., Huang, P., Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 67 (2007), 3512–3517.
20. [20] Gao, N., Rahmani, M., Dent, P., Grant, S., 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 24:23 (2005), 3797–3809.
21. [21] Liang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., Liu, H., Tian, L., Fang, X., Meng, X., et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology 57:5 (2013), 1847–1857.
22. [22] Selvendiran, K., Tong, L., Vishwanath, S., Bratasz, A., Trigg, N.J., Kutala, V.K., Hideg, K., Kuppusamy, P., EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J. Biol. Chem. 282:39 (2007), 28609–28618.
23. [23] Adams, B.K., Cai, J., Armstrong, J., Herold, M., Lu, Y.J., Sun, A., Snyder, J.P., Liotta, D.C., Jones, D.P., Shoji, M., EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16:3 (2005), 263–275.
24. [24] Zou, X., Liang, J., Sun, J., Hu, X., Lei, L., Wu, D., Liu, L., Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway. J. Pharm. Sci., 2016.
25. [25] Chen, W., Zou, P., Zhao, Z., Weng, Q., Chen, X., Ying, S., Ye, Q., Wang, Z., Ji, J., Liang, G., Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation. Oncotarget, 2016.
26. [26] Weinberg, S.E., Chandel, N.S., Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 11:1 (2015), 9–15.
27. [27] Lei, K., Davis, R.J., JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci. USA 100:5 (2003), 2432–2437.
28. [28] Gong, K., Li, W., Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: a potential new treatment for hepatocellular carcinoma. Free Radic. Biol. Med. 51:12 (2011), 2259–2271.
29. [29] Dancey, J.E., Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. 5:9 (2006), 1065–1073.
30. [30] Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl. J. Med. 356:22 (2007), 2271–2281.
31. [31] Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., Grunwald, V., Thompson, J.A., Figlin, R.A., Hollaender, N., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:9637 (2008), 449–456.
32. [32] Ohtsu, A., Ajani, J.A., Bai, Y.X., Bang, Y.J., Chung, H.C., Pan, H.M., Sahmoud, T., Shen, L., Yeh, K.H., Chin, K., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J. Clin. Oncol. 31:31 (2013), 3935–3943.
33. [33] Carew, J.S., Kelly, K.R., Nawrocki, S.T., Mechanisms of mTOR inhibitor resistance in cancer therapy. Target. Oncol. 6:1 (2011), 17–27.
34. [34] Chiarini, F., Lonetti, A., Teti, G., Orsini, E., Bressanin, D., Cappellini, A., Ricci, F., Tazzari, P.L., Ognibene, A., Falconi, M., et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 3:12 (2012), 1615–1628.
35. [35] Szatrowski, T.P., Nathan, C.F., Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:3 (1991), 794–798.
36. [36] Tabas, I., Ron, D., Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13:3 (2011), 184–190.
37. [37] Walter, P., Ron, D., The unfolded protein response: from stress pathway to homeostatic regulation. Science 334:6059 (2011), 1081–1086.
38. [38] Rao, R., Nalluri, S., Fiskus, W., Savoie, A., Buckley, K.M., Ha, K., Balusu, R., Joshi, A., Coothankandaswamy, V., Tao, J., et al. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 16:19 (2010), 4742–4754.
39. [39] Vrablic, A.S., Albright, C.D., Craciunescu, C.N., Salganik, R.I., Zeisel, S.H., Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. FASEB J. 15:10 (2001), 1739–1744.